Welcome to our dedicated page for Achieve Life Sciences SEC filings (Ticker: ACHV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Achieve Life Sciences, Inc. (Nasdaq: ACHV) SEC filings page brings together the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Achieve describes itself as a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline as a treatment of nicotine dependence, and its filings provide formal detail on this business focus, its capital structure, and material events.
Investors reviewing ACHV’s filings can find current reports on Form 8-K that disclose items such as quarterly financial results, executive leadership changes, material definitive agreements, and equity offerings. For example, recent 8-K filings reference press releases announcing financial results, the appointment or resignation of senior officers, and an underwriting agreement for an offering of common stock and warrants under an effective shelf registration statement.
In addition to 8-Ks, Achieve files periodic reports such as Forms 10-K and 10-Q (not reproduced here) that typically include more extensive discussion of its cytisinicline clinical program, risk factors, and financial condition. These documents are central for understanding how the company presents its late-stage development activities, including the FDA’s acceptance of its New Drug Application for cytisinicline for smoking cessation and the status of its vaping cessation program.
On Stock Titan, ACHV filings are updated as they are made available through EDGAR, and AI-powered tools can help summarize lengthy reports, highlight key sections, and surface information about topics such as clinical trial progress, financing arrangements, and governance changes. Users can also review insider and executive-related disclosures reported via Forms 3, 4, and 5 when available, to see transactions and compensatory arrangements that Achieve reports for its officers and directors.
By using this page, readers can quickly locate Achieve’s official SEC documents and use AI-generated insights to better understand how the company reports its operations, cytisinicline development, and material corporate events in a regulatory context.
Achieve Life Sciences Chief Medical Officer Mark Rubinstein filed an initial Form 3 showing his beneficial ownership in the company. As of the event date, he directly holds 39,600 shares of common stock. He also holds stock options to purchase 47,000 shares at $4.52 per share, which became 25% exercisable on September 30, 2025 with the remainder vesting in 36 equal monthly installments, and options to purchase 50,000 shares at $3.10 per share, with 25% becoming exercisable on October 7, 2026 and the rest vesting in 36 equal monthly installments thereafter.
Achieve Life Sciences, Inc. reported an insider equity grant for its Chief Legal Officer on a Form 4. On 12/04/2025, the officer received a stock option to purchase 250,000 shares of common stock at an exercise price of $4.78 per share. The option is exercisable as of 12/04/2025 and has an expiration date of 12/04/2035.
According to the footnote, this option will vest as to one quarter of the total award on the first anniversary of October 20, 2025, and the remaining portion will vest in substantially equal monthly installments over 36 months, subject to continued service with the company on each vesting date. Following this grant, the officer beneficially owns 250,000 derivative securities directly.
Achieve Life Sciences reported Q3 results marked by higher losses and added liquidity. Net loss was $14.4 million for the quarter and $40.0 million for the nine months ended September 30, 2025, driven by R&D of cytisinicline and rising G&A. Cash, cash equivalents, and marketable securities totaled $48.1 million as of September 30, 2025, up from $34.4 million at year-end, reflecting mid‑year financing.
Total assets were $52.0 million and stockholders’ equity was $33.6 million. Operating cash use was $31.5 million year‑to‑date. The company completed a June 2025 public offering of 15,000,000 shares and accompanying warrants, providing $41.2 million in net proceeds, with an additional $4.0 million from partial overallotment exercises. Convertible debt outstanding carried principal of $10.0 million at quarter‑end, with a subsequent $5.0 million tranche drawn in October 2025. Management disclosed substantial doubt about continuing as a going concern absent additional financing. Shares outstanding were 53,233,988 as of November 6, 2025.
Achieve Life Sciences (ACHV)Exhibit 99.1 to an Item 2.02 Form 8-K dated November 6, 2025.
The furnishing designation means the information is not subject to liability under Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Achieve Life Sciences (ACHV) filed an initial statement of beneficial ownership (Form 3) for its Chief Legal Officer. The reporting person indicated no securities beneficially owned (0).
The event date for this filing is 10/20/2025. The form was filed by one reporting person, reflecting the officer’s status and current holdings at the time of the event.
Achieve Life Sciences, Inc. (ACHV) reported an insider acquisition: Chief Operations Officer Craig Donnelly was granted a stock option on 10/01/2025 to purchase 50,000 shares of common stock at a $3.10 exercise price. The option vests with 1/4 of the award on the first anniversary of September 8, 2025 and then in substantially equal monthly installments over the following 36 months, subject to continued service. The Form 4 was signed by an attorney-in-fact on 10/03/2025. This filing documents a routine executive equity award that creates potential future dilution if exercised and ties the officer’s compensation to company share performance.
Mark K. Oki, Chief Financial Officer of Achieve Life Sciences, Inc. (ACHV), reported insider transactions on 09/18/2025. The filing shows settlement of 168,000 performance restricted stock units (PRSUs) into common stock, increasing his beneficial ownership to 178,000 shares immediately after settlement. Concurrently, the reporting person sold 50,060 shares in multiple transactions at a weighted average price of $2.92 per share (individual sale prices ranged from $2.83 to $3.02), reducing beneficial ownership to 127,940 shares. The PRSUs each represent a contingent right to one share and vest upon achievement of specified milestones; the related PRSUs list a date of 12/06/2028 in the filing. The sale is disclosed as made to satisfy income tax withholding and remittance obligations in connection with net settlement.
Richard Stewart, CEO and Director of Achieve Life Sciences (ACHV), reported settlement of performance restricted stock units and related share sales on 09/18/2025. He received 297,500 shares upon settlement of PRSUs and sold 129,501 shares in multiple transactions for a weighted average price of $2.92 per share to satisfy income tax withholding and remittance obligations. After these transactions the filing shows reported beneficial ownership positions including 358,376 shares (direct) and additional indirect holdings: 359 shares held by spouse and 882 held by Ricanto Limited, of which the reporting person is principal. Two tranches of PRSUs (140,000 and 157,500) remain listed with settlement tied to milestone vesting dates in 2028 and 2029.
Craig Donnelly, Chief Operations Officer of Achieve Life Sciences (ACHV), filed an initial Form 3 reporting direct ownership of 52,372 shares of common stock and two stock option awards. One option covers 25,000 shares exercisable beginning 03/14/2033 at $4.53; the other covers 22,500 shares exercisable beginning 01/22/2034 at $4.55. Vesting schedules for each grant are disclosed in the filing.
FAQ
What is the current stock price of Achieve Life Sciences (ACHV)?
What is the market cap of Achieve Life Sciences (ACHV)?
